Heart surgery shock drug trial stalls after just two patients
NCT ID NCT04904562
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested angiotensin II (Giapreza) as a first-line treatment for distributive shock in patients who had a heart transplant or LVAD implant. The goal was to see if it could reduce the need for other blood pressure medications. However, the trial was terminated early after enrolling only 2 out of 40 planned participants, so no meaningful conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Angiotensin II (Giapreza)
- What this could lead to
- If successful, this could point toward a new first-line treatment for shock after heart surgery, potentially reducing the need for other strong medications.
- What could go wrong
- This was a very small pilot study that ended early with only 2 participants, so results are not reliable. The drug may not work better than standard care, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DISTRIBUTIVE SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.